Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Zimmermann

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Clinical Transplantation|February 9, 2016
Selection and use of immunosuppressive therapies after liver transplantation: current German practiceKerstin Herzer, Christian P Strassburg, Felix Braun, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 16, 2012
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIPJörn M Schattenberg, Michael Nagel, Yong Ook Kim, et al.
Plos One|September 20, 2014
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Claus Niederau, Stefan Mauss, Andreas Schober, et al.
Journal of Hepatology|November 15, 2017
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis CPeter Buggisch, Johannes Vermehren, Stefan Mauss, et al.
European Journal of Internal Medicine|August 23, 2018
Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathyChristian Labenz, Larissa Beul, Gerrit Toenges, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 10, 2019
Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantationAnca Zimmermann, Felix Darstein, Maria Hoppe-Lotichius, et al.
BMC Cancer|March 24, 2012
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significanceMichael Heise, Anja Lautem, Johanna Knapstein, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 31, 2015
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvirSebastian Bernuth, Eray Yagmur, Detlef Schuppan, et al.
BMC Cancer|February 14, 2016
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentDaniel Grimm, Jonas Lieb, Veronika Weyer, et al.
International Journal of Oncology|February 27, 2013
Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinomaAnja Lautem, Michael Heise, Andreas Gräsel, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Clinical Transplantation|February 9, 2016
Selection and use of immunosuppressive therapies after liver transplantation: current German practiceKerstin Herzer, Christian P Strassburg, Felix Braun, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 16, 2012
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIPJörn M Schattenberg, Michael Nagel, Yong Ook Kim, et al.
Plos One|September 20, 2014
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Claus Niederau, Stefan Mauss, Andreas Schober, et al.
Journal of Hepatology|November 15, 2017
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis CPeter Buggisch, Johannes Vermehren, Stefan Mauss, et al.
European Journal of Internal Medicine|August 23, 2018
Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathyChristian Labenz, Larissa Beul, Gerrit Toenges, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 10, 2019
Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantationAnca Zimmermann, Felix Darstein, Maria Hoppe-Lotichius, et al.
BMC Cancer|March 24, 2012
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significanceMichael Heise, Anja Lautem, Johanna Knapstein, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 31, 2015
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvirSebastian Bernuth, Eray Yagmur, Detlef Schuppan, et al.
BMC Cancer|February 14, 2016
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentDaniel Grimm, Jonas Lieb, Veronika Weyer, et al.
International Journal of Oncology|February 27, 2013
Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinomaAnja Lautem, Michael Heise, Andreas Gräsel, et al.
Pageof 9